Drugs / RO7062931
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03505190 | May 2018 → Jul 2019 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03038113 | Feb 2017 → Oct 2019 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7062931 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03038113 ↗ |
| Modality | Antisense oligonucleotide | “RO7062931 is an N-acetylgalactosamine (GalNAc)-conjugated single-stranded locked nucleic acid oligonucleotide complementary to HBV RNA.” PMID 34037271 ↗ Aug 2021 |
| Route | Subcutaneous | “Administered subcutaneously in Parts 1 and 2.” NCT03038113 ↗ |